Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Blann

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
American Journal of Respiratory and Critical Care Medicine|March 2, 1999
Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirinB Jilma, A Blann, T Pernerstorfer, et al.
Vox Sanguinis|April 16, 2002
Increased non-transferrin bound iron in plasma-depleted SAG-M red blood cell unitsS S Marwah, A Blann, P Harrison, et al.
Clinical and Experimental Rheumatology|July 15, 2000
A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosisA L Herrick, S Hollis, D Schofield, et al.
Bone Marrow Transplantation|November 1, 1996
Vascular endothelial lesion in patients undergoing bone marrow transplantationS Richard, M Seigneur, A Blann, et al.
British Journal of Cancer|September 9, 2004
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaG Deplanque, S Madhusudan, P H Jones, et al.
Clinical Rheumatology|December 1, 1986
Takayasu's arteritis: a pathogenetic role for cytotoxic T lymphocytes?D G Scott, M Salmon, D L Scott, et al.
Journal of Thrombosis and Haemostasis : JTH|May 5, 2005
Hemostatic abnormalities associated with obesity and the metabolic syndromeG M Reaven, E M Scott, P J Grant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesisJ P Braybrooke, K J O'Byrne, D J Propper, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
American Journal of Respiratory and Critical Care Medicine|March 2, 1999
Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirinB Jilma, A Blann, T Pernerstorfer, et al.
Vox Sanguinis|April 16, 2002
Increased non-transferrin bound iron in plasma-depleted SAG-M red blood cell unitsS S Marwah, A Blann, P Harrison, et al.
Clinical and Experimental Rheumatology|July 15, 2000
A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosisA L Herrick, S Hollis, D Schofield, et al.
Bone Marrow Transplantation|November 1, 1996
Vascular endothelial lesion in patients undergoing bone marrow transplantationS Richard, M Seigneur, A Blann, et al.
British Journal of Cancer|September 9, 2004
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaG Deplanque, S Madhusudan, P H Jones, et al.
Clinical Rheumatology|December 1, 1986
Takayasu's arteritis: a pathogenetic role for cytotoxic T lymphocytes?D G Scott, M Salmon, D L Scott, et al.
Journal of Thrombosis and Haemostasis : JTH|May 5, 2005
Hemostatic abnormalities associated with obesity and the metabolic syndromeG M Reaven, E M Scott, P J Grant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesisJ P Braybrooke, K J O'Byrne, D J Propper, et al.
Pageof 5